You are right. For some reasons I was thinking Leo's initial observations of the ABSSSI trial in which the data were still blinded. OM's interim data should be unblinded. Here's an example:

Intercept Announces NASH Primary Endpoint Met: FLINT Trial Stopped Early for Efficacy Based on Highly Statistically Significant Improvement in Liver Histology

http://ir.interceptpharma.com/releasedetail.c...eid=818119

Quote:

---

Thought the interim data would be unblinded. How do you do an interim evaluation on blinded data?

---